Trade Mark Journal No.2026/007 13 February 2026
WO0000001898575 (5)
Office of origin: United States of America
Date of International Registration:8 September 2025
Date of designation in the UK:
8 September 2025

International priority date claimed: 5 September 2025
(United States of America)
(99376563)
- Class 5
- Pharmaceutical preparations for treating diabetes; medical treatments in the nature of anti-diabetic pharmaceuticals; cell therapy for medical or veterinary use.
Vertex Pharmaceuticals Incorporated
Representative: Sarah Anne Keefe Womble Bond Dickinson (US) LLP, 470 Atlantic Avenue, Suite 600, Boston MA 02210, UNITED STATES OF AMERICA